Formoterol, glycopyrronium
Sold as Glenispera co
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals South Africa (Pty) Ltd | Glenispera co | Not stated | 570048 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glenispera co EACH CAPSULE CONTAINS: GLYCOPYRROLATE EQUIVALENT TO GLYCOPYRRONIUM 12,5 μg ,FORMOTEROL FUMARATE 12,0 μg | Not listed | 57004857/10.2.1/0048 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Formoterol
Consolidated Schedules 06 July 2026, line 6443
S3: Glycopyrronium
Consolidated Schedules 06 July 2026, line 3691
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.